Evidence map›Paper›PMID 30031564›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2018

Biological Variability of Estimated GFR and Albuminuria in CKD.

Sushrut S Waikar, Casey M Rebholz, Zihe Zheng, Shelley Hurwitz, Chi-Yuan Hsu, Harold I Feldman, Dawei Xie, Kathleen D Liu, Theodore E Mifflin, John H Eckfeldt and 6 more

Registry-linked trialAbstract read
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04469842 (A Prospective, Randomized, Controlled Pilot Study of Early-Use Long Acting Tacrolimus), which is not on this map. Cited by 64 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04469842 early_phase1recruitingnot on this mapstarted 2023, after this paper: background citation

A Prospective, Randomized, Controlled Pilot Study of Early-Use Long Acting Tacrolimus (Envarsus XR) in Lung Transplant Recipients

TypeinterventionalSponsorVanderbilt University Medical CenterRan2023 to 2027Enrolled48ConditionsLung Transplant, ComplicationsArmsTacrolimus Extended Release Oral Tablet [Envarsus], Tacrolimus, Mycophenolate Mofetil Hydrochloride, Prednisone, Azathioprine
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Novel protein biomarkers for risk stratification and personalized medicine.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Impact of SGLT2 inhibitors in patients with Fabry disease.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  17. Article
  18. Article
  19. Review
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sushrut S WaikarBrigham and Women's Hospital, Boston, MA. Electronic address: swaikar@partners.org.
Casey M RebholzJohns Hopkins University, Baltimore, MD.
Zihe ZhengJohns Hopkins University, Baltimore, MD.
Shelley HurwitzBrigham and Women's Hospital, Boston, MA.
Chi-Yuan HsuUniversity of California, San Francisco, San Francisco, CA.
Harold I FeldmanUniversity of Pennsylvania, Philadelphia, PA.
Dawei XieUniversity of Pennsylvania, Philadelphia, PA.
Kathleen D LiuUniversity of California, San Francisco, San Francisco, CA.
Theodore E MifflinUniversity of Pennsylvania, Philadelphia, PA.
John H EckfeldtUniversity of Minnesota, Boston, MA.
Paul L KimmelNIDDK, Boston, MA.
Ramachandran S VasanBoston University School of Medicine, Boston, MA.
Joseph V BonventreBrigham and Women's Hospital, Boston, MA.
Lesley A InkerTufts Medical Center, Boston, MA.
Josef CoreshJohns Hopkins University, Baltimore, MD.
Chronic Kidney Disease Biomarkers Consortium Investigators

Funding

KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIRR01DK072381 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2005 to 2025
$8.6M
Mechanisms of Ischemic Kidney Injury and RepairR01DK039773 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI JOSEPH VINCENT BONVENTRE · 1987 to 2026
$6.2M
Proteomic Approach to CKD Biomarker Discovery and ValidationU01DK085689 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2009 to 2019
$5.6M
Chronic Kidney Disease (CKD) Biomarkers Consortium Data Coordinating CenterU01DK103225 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI SCHRAUBEN, SARAH JEANNE · 2014 to 2020
$5.5M
Urinary Biomarkers of Chronic Kidney Disease Pathology and ProgressionU01DK085660 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT, WAIKAR, SUSHRUT S. · 2009 to 2019
$5.3M
Mechanisms of Ischemic Kidney Injury and RepairR37DK039773 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 1993 to 2021
$5.2M
"Validation of Novel CKD Biomarkers in CRIC"U01DK085649 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN, LIU, KATHLEEN D · 2009 to 2013
$4.4M
The New York CKD Biomarker Discovery ProgramU01DK085688 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BOTTINGER, ERWIN P. · 2009 to 2013
$3.0M
Urinary Biomarkers in Biopsy Defined Early Nephropathy in Types 1 and 2 DiabetesU01DK085651 · NIDDK · UNIVERSITY OF MINNESOTA · PI MAUER, S. MICHAEL · 2009 to 2013
$2.2M
Discovery & Validation of Biomarkers of Kidney PathologyU01DK096927 · NIDDK · OHIO STATE UNIVERSITY · PI ROVIN, BRAD H · 2013 to 2017
$2.0M
Forecasters of futute and progressive CDK in patients with microvascular glomerulU01DK085673 · NIDDK · OHIO STATE UNIVERSITY · PI KLEIN, JON, ROVIN, BRAD H · 2009 to 2013
$2.0M
Novel Human Biomarkers of Kidney FibrosisU01DK104308 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI HUMPHREYS, BENJAMIN D., WAIKAR, SUSHRUT S. · 2014 to 2018
$2.0M
NIDDK NIH HHS K01 DK107782NIDDK NIH HHS R01 DK039773NIDDK NIH HHS R01 DK072381NIDDK NIH HHS R37 DK039773NIDDK NIH HHS U01 DK085649NIDDK NIH HHS U01 DK085651NIDDK NIH HHS U01 DK085660NIDDK NIH HHS U01 DK085673NIDDK NIH HHS U01 DK085688NIDDK NIH HHS U01 DK085689NIDDK NIH HHS U01 DK096927NIDDK NIH HHS U01 DK103225NIDDK NIH HHS U01 DK104308
6 · The paper itself

Abstract

RATIONALE &

objectiveDetermining whether a change in estimated glomerular filtration rate (eGFR) or albuminuria is clinically significant requires knowledge of short-term within-person variability of the measurements, which few studies have addressed in the setting of chronic kidney disease. STUDY

designCross-sectional study with multiple collections over less than 4 weeks. SETTING &

participantsClinically stable outpatients with chronic kidney disease (N=50; mean age, 56.8 years; median eGFR, 40mL/min/1.73m EXPOSURE: Repeat measurements from serially collected samples across 3 study visits. OUTCOMES: Measurements of urine albumin concentration (UAC), UACR, and plasma creatinine, cystatin C, β ANALYTICAL APPROACH: We calculated within-person coefficients of variation (CV

resultsMedian CV LIMITATIONS: Small sample size limits the ability to detect differences in variability across markers. Participants were recruited and followed up in a clinical and not research setting, so some preanalytical factors could not be controlled.

conclusionseGFR markers appear to have relatively low short-term within-person variability, whereas variability in albuminuria appears to be high, making it difficult to distinguish random variability from meaningful biologic changes.

Indexed as

AdultAgedAlbuminuriabeta 2-MicroglobulinBiomarkersBlood Chemical AnalysisCreatinineCross-Sectional StudiesCystatin CFemaleGlomerular Filtration RateHumansIntramolecular OxidoreductasesLipocalinsMaleMiddle Agedbeta 2-MicroglobulinBiomarkersCreatinineCystatin CIntramolecular OxidoreductasesLipocalinsprostaglandin R2 D-isomeraseAlbuminuriabeta trace protein (BTP)biological variabilitybiomarkerclinically meaningful differencescoefficient of variation (CV)cystatin Cestimated glomerular filtration rate (eGFR)filtration markerintraindividual variationkidney functionlaboratory measurementreproducibilityserum creatinineurinary albumin-creatinine ratio (UACR)β(2)-microglobulin (B2M)

Identifiers

PMID30031564
PMCPMC6469385

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.